<DOC>
	<DOCNO>NCT00355251</DOCNO>
	<brief_summary>To determine influence atorvastatin plasma viral replication latter give highly active anti-retroviral therapy ( HAART ) patient HIV infection viral suppression .</brief_summary>
	<brief_title>Influence Atorvastatin Viral Replication During Antiretroviral Treatment Interruption</brief_title>
	<detailed_description>Recently , inhibitory effect statins replication human immunodeficiency virus Type 1 ( HIV-1 ) two independent mechanism action describe : blockade Rho guanosine triphosphatase intervenes entry exit virus blockade interaction LFA-1 ( leukocyte function antigen 1 ) ICAM 1 ligand ( intercellular adhesion molecule 1 ) intervenes process virus bind target cell . These initial data lead study effect atorvastatin plasma replication HIV HIV+ patient interrupt antiretroviral therapy ( Ator Study 3 ) develop unit . The data study indicate baseline plasma cholesterol determine viral load rebound interrupt antiretroviral treatment . However , introduction atorvastatin day interruption provide virological immunological benefit comparison interruption antiretrovirals without statin . This may due fact potent inhibitory effect atorvastatin unable compensate activate effect production HIV also describe study . Overall , result pose possible usefulness atorvastatin control viral replication give interruption antiretroviral therapy due : - Their capacity reduce serum cholesterol time interruption consequently cholesterol cell membrane . - Their potent capacity purge HIV reservoir Therefore , study aim investigate impact atorvastatin viral replication give 8 week interruption antiretroviral treatment determine whether impact due reduction serum and/or membrane cholesterol , whether , hand , contribution atorvastatin 's capacity induce expression viral product .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Age &gt; = 18 year . 2 . Patients chronic infection HIV1 stable highly active antiretroviral treatment ( &gt; = 6 month ) . 3 . Undetectable plasma viral load ( &lt; 50 copies/mL ) last 3 determination last 6 month . 4 . CD4 &gt; 500 cells/mm &gt; =3 last two determination . 5 . Documented prior viral load time &gt; 15,000 copies/mL . 6 . Women may fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , must undertake use barrier contraceptive method study . 7 . Signature inform consent 1 . CD4 nadir &lt; = 200 cells/mm3 . 2 . Background infection AIDSdefining pathology . 3 . Intercurrent infection last 6 month . 4 . Creatine kinase ( CK ) &gt; = 500 U/L . 5 . AST ALT &gt; = 3 time high upper limit normality . 6 . Treatment others statin , fibrates , macrolides fluconazole last 3 month . 7 . Pregnancy breastfeed 8 . Patients participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>Viral replication</keyword>
	<keyword>HIV-1</keyword>
	<keyword>plasma cholesterol</keyword>
	<keyword>Cell membrane cholesterol</keyword>
</DOC>